BROSSARD, Quebec, Sept. 03, 2019 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the extension of the automated detection of Diabetic Retinopathy at the CHUM (Centre hospitalier de l’Université de Montréal) until the end of 2019.
Launched in June 2018 in collaboration with the ophthalmology and endocrinology department, the technology showcase has allowed more than a thousand patients from the CHUM to access screening technology. DIAGNOS will continue to be present at the CHUM until the end of 2019 to test the latest algorithms being released for full automated environment.
“This technological showcase is very important to us. We have been able to demonstrate it’s capability and save vision of patients. We continue to demonstrate our expertise to our future Canadian and international clients. We can present the precision of our algorithms in the detection and classification of the patients in order of the severity of the disease. The CHUM is now showing us how they use our technology in their operations and we are learning from them while improving our offering, said Yves-Stephane Couture, Vice President at DIAGNOS.
DIAGNOS has screened to date more than 300,000 diabetic patients. Thanks to the support of the Government of Quebec and our collaboration with the CHUM, this technological showcase keeps helping DIAGNOS to demonstrate our expertise in the province. We strongly believe this project will also help set up extensive screening campaigns in other Canadian provinces and in the United States.
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.
For further information, please contact:
Mr. André Larente, President
Tel: 450-678-8882 ext. 224
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.